8 June 2021 - The biotech company’s price for the drug is higher than the $10,000 to $25,000 some Wall Street analysts were expecting.
Biogen on Tuesday faced tough questions from Wall Street analysts over the $56,000 annual cost of its newly approved Alzheimer’s drug, Aduhelm – a price tag executives are calling “fair” and “responsible.”